←
UCSF Team for High-Value Care125 posts
UCSF Team for High-Value Care avatar

UCSF Team for High-Value Care

@UCSF_HVC

@UCSF-based team working to promote high-value care within the U.S. health care system.

◷ Joined August 2021▧ 3 Photos and videos
UCSF Team for High-Value Care avatar
UCSF Team for High-Value Care@UCSF_HVC·Oct 21

New research from our team in @bmj_latest finds that medical device adverse events are still being reported within summary reports that are frequently incomplete, inaccurate, and delayed, despite FDA's decision in 2019 to end a similar program due to transparency concerns

Permitting medical device manufacturers to submit bulk summary reports of adverse events to the US Food and Drug Administration, rather than reporting individual cases, often fails to promptly detect potential safety signals, finds new study in The BMJ bmj.com/content/395/bmj-2026…

UCSF Team for High-Value Care avatar
UCSF Team for High-Value Care@UCSF_HVC·Oct 15

Tune into the GeriPal podcast to hear more from @RFRedberg on the evidence for statins in older adults! #deprescribing

New guidelines make 90%+ of #OlderAdults eligible for #statins, but should they take them? New PREVENT risk calculator, STAREE trial findings, and the safety of #deprescribing after 75 with @RFRedberg, Tim Anderson & Mike Rich. - bit.ly/GeriPalEp420 @AlexSmithMD | @EWidera

1:17
UCSF Team for High-Value Care avatar
UCSF Team for High-Value Care@UCSF_HVC·9 Jul 2024

Important piece on MitraClip in @KFFHealthNews – serious adverse events, three recalls, questions of biased data and conflicts of interest and inconsistent evidence of effectiveness raise concerns about use of the device

NEW: The story of MitraClip, a device Dr. Oz helped invent to treat faulty heart valves, is a cautionary tale about the science, business, and regulation of medical technology. @DavidHilzenrath & @hollyhacker report. ⤵️ kffhealthnews.org/news/artic…

UCSF Team for High-Value Care avatar
UCSF Team for High-Value Care@UCSF_HVC·3 Jul 2024

Investing time to generate mortality data for MCEDs is in patients' best interest - moving forward without evidence that MCEDs save patient lives is not and likely to be harmful, as @RFRedberg & coauthors wrote in @JAMAInternalMed: doi.org/10.1001/jamainternme…

STAT@statnews24 Jun 2024

#News After a decade of drama, Grail goes public with high hopes for its multi-cancer blood test but also many issues yet to settle. trib.al/YiZ5w4Z

UCSF Team for High-Value Care avatar
UCSF Team for High-Value Care@UCSF_HVC·1 Jul 2024

Moving forward with MCED tests without evidence that they save patient lives is inappropriate. Medicare coverage of MCEDs should require high-quality evidence, from RCTs, of mortality benefit from these tests @CMSGov

STAT@statnews29 Jun 2024

Grail CEO Bob Ragusa told STAT: "Adding Galleri to standard of care screening creates a powerful and efficient cancer screening system." trib.al/srl2vdv

UCSF Team for High-Value Care avatar
UCSF Team for High-Value Care@UCSF_HVC·27 Jun 2024

This study builds on prior research in @JAMA_current by the author team that found that financial conflicts of interest are common but rarely disclosed by public commenters on NCDs: doi.org/10.1001%2Fjama.2023.…

UCSF Team for High-Value Care avatar
UCSF Team for High-Value Care@UCSF_HVC·27 Jun 2024

Analysis of public comments on @CMSGov National Coverage Determinations for therapeutic medical devices finds most of the cited articles were funded by manufacturers who would profit from an NCD expanding coverage.

UCSF Team for High-Value Care avatar
UCSF Team for High-Value Care@UCSF_HVC·11 Jun 2024

From Sanket Dhruva & @RFRedberg: Given harms of overdiagnosis, early is not always better for cancer. Liquid biopsy trials must show reduction in all-cause death to claim they save lives - Only then will we know if healthy people benefit from these tests @US_FDA @FDADeviceInfo

STAT@statnews11 Jun 2024

The potential for irreversible harms from liquid biopsy blood tests is significant, in addition to the staggering cost. trib.al/ymtN64z